Overview
The marketing activities of companies in the health care and life sciences sectors draw far more regulatory scrutiny than most other industries. As new and innovative products come to market, the companies behind them must navigate a dense regulatory environment in which any marketing misstep can carry onerous repercussions, both legal and reputational.
Our lawyers take a pragmatic, multidisciplinary approach to the strategic and tactical considerations of our clients’ product marketing efforts. This lets our clients market as aggressively as their risk level allows while maintaining compliance with regulatory requirements.
Analyzing Marketing Materials
We regularly serve on our clients’ promotional review committees, where they trust us to become part of the team tasked with implementing effective marketing and promotional content while mitigating legal and compliance risks. We advise our clients on pre- and post-approval product communications, helping them navigate divergent rules for their scientific, promotional, and investor communication. Our team regularly guides clients regarding substantiation of their product claims, ensuring that they comply with U.S. Food and Drug Administration (FDA) and Federal Trade Commission advertising and promotion rules. We also assess their competitors’ communications and will reach out to regulators on behalf of our clients who are concerned about dubious products or product claims entering the market.
Marketing on Social Media
The rise of social media as a mainstream marketing tool has brought with it regulatory challenges that continue to evolve. Our clients trust us to stay abreast of compliance issues associated with novel marketing platforms and approaches to enable them to quickly maneuver and take advantage of new opportunities. We review their strategies and promotional materials, recommending guardrails to mitigate risks associated with their use. We advise them on the training and use of product influencers, and we help them put in place the controls—both contractual and procedural—that maintain optimal compliance in online environments.
Read less
Focus Areas
Experience
- Represented numerous individual companies and trade associations in their efforts to ensure that health care economic information was appropriately shared while maintaining compliance with FDA requirements.
- Advised pharmaceutical and biotechnology companies on compliance-related issues in order to support the development and commercialization of their products.
- Conducted an assessment of a large, global medical device company’s development and use of health economic and reimbursement information in its promotional materials. Based on the results, we developed policies to ensure the appropriate use of this information and trained the company's personnel on the regulatory framework governing the use of the information.
- Assisted a large medical device manufacturer in developing and successfully implementing a comprehensive system of Good Promotional Practices that achieved both compliance and the manufacturer's marketing objectives.
- Helped many companies successfully respond to FDA Warning Letters challenging their promotional activities, often representing them in associated meetings with the FDA and other federal agencies.
Contacts
- Member of the Firm
- Board of Directors / Member of the Firm
- Member of the Firm
Media
Events
Past Events
- December 10-11, 2024
- September 28, 2021
Insights
Insights
- Blogs
Aligning Business Goals with Legal Strategies Amid Regulatory Change – Speaking of Litigation Video Podcast
41 minute read - Media CoverageJames Boiani Quoted in “Will Trump Admin. ‘Wash Its Hands’ of FDA Lab-Test Rule?”2 minute read
- Media CoverageJames Boiani Quoted in “Drug Industry Worries About FDA Delays”3 minute read
- PublicationsACIP’s Upcoming Meningococcal Recommendations: Added Complexity, Reduced Choice1 minute read
- PublicationsCMS Rule for CY 2026 Highlights AI, Behavioral Health, Anti-Obesity Drug Coverage, and More24 minute read
- Media CoverageJames Boiani Quoted in “Supplement Makers Try to Latch On to GLP-1 Boom”2 minute read
- Media CoverageBBA Spotlight Series: Get to Know Emerging Leaders in Boston Law–Marylana Saadeh Helou8 minute read
- Blogs
Litigating Nutrition: Class Action Battles Over Dietary Supplements – Speaking of Litigation Video Podcast
41 minute read - Media CoverageJames Boiani Quoted in “Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval”5 minute read
- Media CoverageBob Hearn Quoted in “Concerns Mount as More States Adopt Biomarker Laws”2 minute read
- PublicationsEnsure Equity and Feasibility in Updating Meningococcal Vaccine Recommendations2 minute read
- Firm AnnouncementsEpstein Becker Green Announces 2024 Promotions6 minute read
- BlogsSharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft ...14 minute read
- BlogsInfluencers, Brand Ambassadors and Marketers Take Note – FTC Has Finalized Updates to Its Endorsement Guides7 minute read
- PublicationsDietary Supplement Makers Face "Misbranding" Minefield, Need FDA Guidance7 minute read
- Firm Announcements
Jessika Tuazon Named to the 2023 Southern California Rising Stars List
6 minute read - Media CoverageJames Boiani Quoted in “FDA Resumes Move to Regulate LDTs, Likely Setting Up Legal Battle with Lab Industry” ...3 minute read
- Media CoverageJames Boiani, Bradley Merrill Thompson Quoted in “And Over at FDA …”2 minute read
- PublicationsFTC’s Revisions to Dietary Supplement Advertising Guidelines: More of the Same2 minute read
- Media CoverageJames Boiani Quoted in “Congress Has a Chance to Close the FDA’s Theranos Loophole”3 minute read
- Media CoverageOffice Snapshot: Epstein Becker Green's New Nashville Outpost3 minute read
- Firm AnnouncementsEpstein Becker Green Announces 2023 PromotionsOctober 28, 20225 minute read
- Media CoverageJames Boiani Quoted in “Testing Overhaul Faces a ‘Narrow Pathway’ to Pass Before Year End, Industry Groups Say” ...3 minute read
- Firm Announcements
Epstein Becker Green’s Amy Dow Honored in Crain’s 2022 Notable Women in Law
2 minute read - Media CoverageEpstein Becker Green’s Unpacking Averages Report “Casts Doubt on Value of US FDA’s Breakthrough Devices Program” ...2 minute read
- PublicationsRecent Actions Highlight That Price Fixing Reaches Beyond Agreements on the Ultimate Price1 minute read
- Firm Announcements
Jessika Tuazon Named to the 2022 Southern California Rising Stars List
5 minute read - Firm AnnouncementsEpstein Becker Green’s Theodora McCormick Recognized as a Trailblazing Change-Maker by the Executive Women of New Jersey ...4 minute read
- Firm Announcements
Thirteen Attorneys Named to the 2022 Washington, DC, Super Lawyers and Rising Stars Lists
5 minute read - Firm AnnouncementsEpstein Becker Green’s Managing Director James P. Flynn Named a “Leader in Law”4 minute read
- Firm AnnouncementsEpstein Becker Green Announces 2022 Promotions6 minute read
- Media CoverageJames Boiani Quoted in “Covid Test Makers Told to Update Labeling in Wake of Mutations”2 minute read
- Firm Announcements
Ten Epstein Becker Green Attorneys Named to 2021 Washington, DC, Super Lawyers and Rising Stars Lists
5 minute read - PublicationsDistinguishable Products and Tying Claims in Health Care Markets3 minute read
- Media CoverageJames Boiani Quoted in “Regulatory Attorney Says Warning Letters Likely to Spike Under New FDA Administration” ...3 minute read
- PublicationsBusinesses Beware: FTC Seeks to Codify “Made in USA” Enforcement Policy4 minute read
- Media CoverageJames Boiani Quoted in "Startups Spar with FDA Over What Constitutes a Home Coronavirus Test"3 minute read
- PublicationsFDA and FTC Join Forces to Promote Biosimilars3 minute read
- PublicationsChapter 6, "Federal Health Care Programs: Coverage and Reimbursement of Prescription Drugs and Medical Devices ...2 minute read
- Media CoverageAlaap Shah Quoted in "Can Pacemakers (and Other Medical Devices) Really Be Hacked?"2 minute read
- Media CoverageJames Boiani Quoted in "At-Home Tests for Influenza, Strep, Others Raising Eyebrows of Some Experts"2 minute read
- Media CoverageRobert Wanerman Quoted in "Trump Might Pay for Some Devices Before Medicare Approval: Industry"3 minute read
- Media CoverageJames Boiani Quoted in "Device Lawyer: FDA Guidances Provide Clarity on Payer Communication"2 minute read
- PublicationsCheers to 80 Years of the Food, Drug, and Cosmetic Act1 minute read
- Media CoverageJames Boiani Quoted in "Nicotine Replacement Trials and the App Effect"3 minute read
- Firm Announcements
Epstein Becker Green Named a 2017 "Health Practice Group of the Year" by Law360
2 minute read - Media Coverage
"FDA Guidance on Decision Support Software: Implications for Industry" Featured in POLITICO Morning eHealth
2 minute read - Media Coverage
Jack Wenik's Presentation on Dietary Supplement Litigation Featured in Natural Products INSIDER
2 minute read - Media CoverageJames Boiani Quoted in "FDA Final Guidance on Drug/Device Classifications Misses the Mark, Attorneys Say"2 minute read
- Media CoverageJames Boiani Quoted in "Combo Product Appeals Low in Number, but Lengthy in Decision Time"2 minute read